SEC Tracker
Get the app

Dexcom DXCM

Dexcom Q2 FY25: revenue $1.2B, up 15%; diluted EPS $0.45

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Dexcom reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.2B+15% from $1.0B in Q2 FY2410-Q income statement, on EDGAR
  2. Net income$179.8M+25% from $143.5M in Q2 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.45+29% from $0.35 in Q2 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.2B+23% from $939.2M in Q2 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations$303.0M+8% from $279.4M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Dexcom files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Resmed RMD public float $34.9B, Dec 31, 2025
  2. Insulet PODD public float $22.1B, Jun 30, 2025
  3. Baxter International BAX public float $16.0B, Jun 30, 2025
  4. West Pharmaceutical Services WST public float $15.7B, Jun 30, 2025
  5. Solventum SOLV public float $13.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.